Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of apatinib in first-line chemotherapy-refractory recurrent or metastatic cholangiocarcinoma
ChiCTR2100046565Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2100046565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046565.